Holen Sie sich die Stockscreener-App
15.76
1.25%
-0.20
Handel nachbörslich:
15.76
Schlusskurs vom Vortag:
$15.96
Offen:
$16.01
24-Stunden-Volumen:
2.44M
Relative Volume:
1.08
Marktkapitalisierung:
$2.41B
Einnahmen:
$205.22M
Nettoeinkommen (Verlust:
$-121.24M
KGV:
-19.36
EPS:
-0.8141
Netto-Cashflow:
$-82.81M
1W Leistung:
-0.94%
1M Leistung:
+6.06%
6M Leistung:
+32.10%
1J Leistung:
+135.58%
1-Tages-Spanne:
$15.45
$16.29
1-Wochen-Bereich:
$15.31
$17.33
52-Wochen-Spanne:
$5.975
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Vergleichen Sie ADPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
15.76 | 2.44B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Insider Sell: Harlan Robins Sells Shares of Adaptive Biotechnolo - GuruFocus
Adaptive Biotechnologies CSO Robins sells $164k in shares - Investing.com
Meme Stocks: Will Adaptive Biotechnologies Corporation (1HM) stock profit from automation waveMarket Movers & Smart Money Movement Alerts - ulpravda.ru
Adaptive Biotechnologies assumed with an Equal Weight at Morgan Stanley - MSN
Adaptive Biotechnologies Insider Sold Shares Worth $1,948,719, According to a Recent SEC Filing - MarketScreener
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies Cor - GuruFocus
Adaptive Biotechnologies CEO Robins sells $1.95 million in shares - Investing.com
Adaptive Biotechnologies CEO Sells Over $1.9 Million in Company Stock - TradingView — Track All Markets
Adaptive Biotechnologies CPO Lo sells $50k in ADPT stock By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CPO Lo sells $50k in ADPT stock - Investing.com India
Adaptive Biotechnologies discloses it's raising $15 million for subsidiary - The Business Journals
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech company heads to major healthcare conference in San Francisco - Stock Titan
Adaptive Biotechnologies announces subsidiary’s Series A financing round By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CorpUnit held initial closing $15 million Series A financingSEC filing - marketscreener.com
Adaptive Biotechnologies announces subsidiary’s Series A financing round - Investing.com
Adaptive Biotechnologies Announces Series A Financing for Subsidiary - TradingView — Track All Markets
Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock By Investing.com - Investing.com South Africa
Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock - Investing.com
Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle (ADPT) - Seeking Alpha
Adaptive Biotechnologies (ADPT) Leads Life Sciences Sector with 183.57% YTD Gain - GuruFocus
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer T-Cell Discovery and AI Drug Collaboration Deals - simplywall.st
Adaptive Biotechnologies is the top performing life sciences tools and services stock YTD (ADPT:NASDAQ) - Seeking Alpha
Adaptive Biotechnologies (ADPT) Is Up 10.1% After New Pfizer TCR-AI Collaboration Milestone DealWhat's Changed - simplywall.st
Will Adaptive Biotechnologies Corporation stock see PE expansionTrade Risk Summary & Real-Time Market Trend Scan - Улправда
How Adaptive Biotechnologies Corporation (1HM) stock trades after rate cutsGlobal Markets & High Accuracy Trade Signal Alerts - Улправда
How Adaptive Biotechnologies Corporation stock responds to policy changesMarket Activity Recap & Fast Moving Stock Trade Plans - Улправда
First Week of February 2026 Options Trading For Adaptive Biotechnologies (ADPT) - Nasdaq
Why Adaptive Biotechnologies Corporation stock remains undervaluedJuly 2025 Technicals & Trade Opportunity Analysis Reports - Улправда
Adaptive Biotechnologies Insider Sold Shares Worth $1,773,267, According to a Recent SEC Filing - MarketScreener
Adaptive Biotechnologies Exec Sells Shares Under Trading Plan - TradingView — Track All Markets
Officer Lo Sells 113,890 ($1.8M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
[Form 4] Adaptive Biotechnologies Corp Insider Trading Activity - Stock Titan
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer Collaborations and Surging 2024 Share Price - simplywall.st
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M - Investing.com
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst - Benzinga
Adaptive Biotechnologies inks two agreements with Pfizer in immunology - Investing.com India
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M By Investing.com - Investing.com South Africa
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Yahoo Finance
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - The Manila Times
How Investors Are Reacting To Adaptive Biotechnologies (ADPT) clonoSEQ Data Shaping MRD-Guided Cancer Care - Yahoo Finance
Insider Sell: Robert Hershberg Sells 22,968 Shares of Adaptive B - GuruFocus
Adaptive Biotechnologies Director Sells Shares - TradingView — Track All Markets
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Dir Hershberg Files To Sell 22,968 Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
Take off with Adaptive Biotechnologies Corp (ADPT): Get ready for trading - setenews.com
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - The Manila Times
Adaptive Biotechnologies to Discuss clonoSEQ Technology and Minimal Residual Disease at Jefferies Fireside Chat - Quiver Quantitative
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adaptive Biotechnologies Corp-Aktie (ADPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROBINS CHAD M | CEO and Chairman |
Jan 05 '26 |
Sale |
15.59 |
124,998 |
1,948,719 |
2,584,243 |
| LO FRANCIS | Chief People Officer |
Jan 02 '26 |
Option Exercise |
3.99 |
3,125 |
12,469 |
319,103 |
| LO FRANCIS | Chief People Officer |
Jan 02 '26 |
Sale |
16.08 |
3,125 |
50,250 |
315,978 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):